Clinical Trial Update: A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC [Phase 2]

View source ↗

Summary

Phase II study investigating cemiplimab plus ISA101b in HPV16-positive oropharyngeal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Oropharynx

Drugs mentioned

• Cemiplimab (cemiplimab)
• ISA101b (ISA101b)

Snippet

Sponsor: ISA Pharmaceuticals | Conditions: Squamous Cell Carcinoma of the Oropharynx | Phase 2 | Status: UNKNOWN